Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use

• Status: Not yet recruiting
• Trial end date: 2022-02-26
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the effect of continuation of buprenorphine/naloxone in patients with history of Opioid Use Disorder (OUD) scheduled for surgery compared to reduced dose buprenorphine/naloxone prior to surgery on pain scores, opioid consumption, depressive symptoms and severity of substance use dependence- including record of problematic use of any non-prescribed opioids, alcohol and illicit narcotics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• currently taking buprenorphine or buprenorphine/naloxone daily for treatment of opioid use disorder by DSM-V criteria

• on buprenorphine or buprenorphine/naloxone dose of greater than 8mg for at least 30 days

• ASA health class I-III

Exclusion Criteria:

• Unable to consent to the study

• Significant pulmonary or cardiac disease

• Renal insufficiency with a glomerular filtration rate less than 30ml/min

• Liver cirrhosis with a Model for End-Stage Liver Disease (MELD) score of greater than 25